ClinicalTrials.gg
CompletedNCT03332212Updated Jun 18, 2021Results posted

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

A Phase 3 interventional study of Empagliflozin and Placebo in Heart Failure, sponsored by Boehringer Ingelheim. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-18.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Enrollment
32nd of 51
72 · median 90
Started
2018
with 4 others
Phase 3
14 of 51
5 open now
Registered
10th of 51
by date
Lead sponsor
6 of 51
Boehringer Ingelheim

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 32nd largest by enrollment, is one of 5 that started in 2018, is one of 14 in phase 3, and was the 10th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The objective of this trial is to assess the effect of empagliflozin on cardiac physiology and metabolism aiming to provide a scientific explanation of the underlying mechanism by which empagliflozin improves HF related outcomes in patients with chronic heart failure

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic heart failure diagnosed at least 3 months before
  • class II-IV at screening
  • Age ≥ 18 years at screening
  • Male or female patients. Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Cohort A Heart Failure with Reduced (HFrEF)

  • Left ventricular ejection fraction (LVEF) ≤ 40% as measured by ECHO at screening
  • The following signs of heart failure;

    • Elevated NT-proBNP (>125 pg/mL) at screening in patient without atrial fibrillation (AF)
    • Elevated NT-proBNP (>600 pg/mL) at screening in patient with AF
  • Appropriate dose of medical therapy for HF (such as ACEi, ARB, β-blocker, oral diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international HF guidelines, stable for at least one week prior to Visit 1 and during screening period until Visit 2 (Randomisation) with the exception of diuretics which must be stable for at least one week prior to Visit 2 to control symptoms. If required, the investigator must document in the source documents the reason why the patient is not on the target dose per local guidelines.

Cohort B Heart Failure with Preserved Ejection Fraction (HFpEF)

  • Left ventricular ejection fraction (LVEF) ≥ 50% as measured by ECHO at screening and no previous measurement of LVEF ≤ 40%.
  • The following combined signs of heart failure;

    • Structural heart disease (LA enlargement [LAVI >34 mL/m2] and/or LVH [LVMI ≥ 115 g/m2 for males and ≥ 95 g/m2 for females]) by ECHO at screening or within 3 months prior to informed consent AND
    • NT-proBNP > 125pg/mL at screening in patient without AF or NT-pro-BNP > 600 pg/mL in patient with AF
  • Oral diuretics, if prescribed, should be stable for at least one week prior to Visit 1 and during screening period until Visit 2 (Randomisation).

Exclusion criteria

Exclusion Criteria:

  • Stroke or (TIA) within 6 months prior to .
  • Any patients with myocardial scars and/or non-viable myocardium in the interventricular septum, unstable angina due to significant coronary artery disease (CAD), or major (in the opinion of the investigator) cardiovascular surgery.
  • Any for MRI, CPET and/or dobutamine stress test in accordance with the institution guidance, including implanted left ventricular assist device (LVAD),implantable cardioverter defibrillator (ICD), cardiac resynchronisation therapy (CRT) or any cardiac device.
  • Heart transplant recipient or listed for heart transplant
  • Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction
  • Moderate to severe uncorrected valvular heart disease, obstructive or regurgitant, or any valvular heart disease expected to lead to surgery in the Investigator's opinion
  • Acute decompensated HF (exacerbation of chronic HF) requiring intravenous (i.v.) diuretics, i.v. inotropes or i.v. vasodilators, or LVAD or hospitalisation within 1 week prior to Visit 1 (Screening), or during screening period until Visit 2 (Randomisation)
  • Systolic blood pressure (SBP) ≥ 180 mmHg at screening. If SBP >150 mmHg and \<180mmHg at screening, the patient is ineligible if receiving 3 or more antihypertensive drugs
  • Symptomatic hypotension and/or a SBP \< 100 mmHg at Screening
  • Atrial fibrillation which is uncontrolled in the opinion of the investigator
  • Untreated ventricular arrhythmia with syncope documented within the 3 months prior to informed consent in patients without ICD
  • Diagnosis of cardiomyopathy induced by chemotherapy or peripartum within the 12 months prior to informed consent
  • Symptomatic bradycardia or second or third degree heart block in need of a pacemaker after adjusting beta-blocker therapy or any other negative inotropic agents, if appropriate
  • Chronic pulmonary disease requiring home oxygen, oral therapy or hospitalisation for exacerbation within 12 months prior to informed consent, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension
  • Indication of liver disease, defined by serum levels of either (SGPT), AST (SGOT),or alkaline phosphatase above 3 x (ULN) as determined at screening
  • Impaired renal function, defined as estimated \< 30 mL/min (using Cockcroft-Gault formula) or requiring dialysis, as determined at screening
  • \< 10 g/dL at screening
  • Type 1 Diabetes Mellitus (T1DM)
  • History of ketoacidosis
  • Major surgery (major according to the investigator's assessment) performed within 3 months prior to informed consent, or scheduled major elective surgery (e.g. hip replacement) within 3 months after Visit 1
  • Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion
  • Any documented active or suspected or history of malignancy within 6 months prior to informed consent, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA \<10 ng/mL, and Gleason score of ≤ 6 and clinical stage T1c or T2a)
  • Presence of any other disease than heart failure with a of \<1 year in the investigator's opinion
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Patients with requirement for treatment with empagliflozin according to local standard of care
  • Treatment with any SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor within 1 week prior to informed consent or during screening period until Visit 2 (Randomisation)
  • Currently enrolled in another device or drug study, or less than 30 days between randomisation and ending another investigational device or drug study, or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded.
  • Known allergy or to empagliflozin or other SGLT-2 inhibitors
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial
  • Women who are pregnant, breastfeeding, or who plan to become pregnant while in the trial
  • Any clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort A (Empagliflozin + Placebo)

    Heart Failure with Reduced Ejection Fraction

    Drug: Empagliflozin · Drug: Placebo

  • Experimental
    Cohort B (Empagliflozin + Placebo)

    Heart Failure with Preserved Ejection Fraction

    Drug: Empagliflozin · Drug: Placebo

Interventions

  • 12 weeks

    Also known as: JARDIANCE, JARDIANZ, GIBTULIO

  • DrugPlacebo

    12 Weeks

    Also known as: JARDIANCE, JARDIANZ, GIBTULIO

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).

    The primary endpoint of efficacy was the change from baseline to Week 12 in phosphocreatine/adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy (MRS). Adjusted mean values were calculated using an analysis of variance (ANOVA) model, with treatment, history of diabetes, and history of atrial fibrillation (AF) as fixed effects.

    Time frame: At baseline and at week 12.

07

Results

Posted Jun 18, 2021
Limitations and caveats
Due to the suspension of face-to-face contact imposed in March 2020 to restrict transmission of COVID-19, the number of patients included in the analysis of efficacy for the Heart failure with preserved ejection fraction was substantially reduced, which meant that this cohort was also under powered (reduced from 80% to 70%) for the planned analysis of the primary endpoint.

Participant flow

A randomised, double-blind, placebo controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with heart failure.

Participant flow — Overall Study
MilestonePlacebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort B
Started19181718
Treated19171718
Completed18161717
Not completed1201
Withdrew: Not treated0100
Withdrew: Adverse event0001
Withdrew: Worsening of disease under study1100

Outcome measures

PrimaryChange From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).

The primary endpoint of efficacy was the change from baseline to Week 12 in phosphocreatine/adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy (MRS). Adjusted mean values were calculated using an analysis of variance (ANOVA) model, with treatment, history of diabetes, and history of atrial fibrillation (AF) as fixed effects.

Time frame:
At baseline and at week 12.
Reported as:
Least squares mean · PCr / ATP Ratio
Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).
PCr / ATP RatioPlacebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort B
Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).0.068 ± 0.1140.259 ± 0.156-0.179 ± 0.1170.100 ± 0.143
Statistical analysis
  • Placebo Cohort A vs Empagliflozin 10mg Cohort A · ANOVA · p = 0.1418 · Mean difference (final values): -0.247 · 95% CI -0.582 to 0.087
  • Placebo Cohort B vs Empagliflozin 10mg Cohort B · ANOVA · p = 0.4650 · Mean difference (final values): -0.159 · 95% CI -0.604 to 0.286

Adverse events

Collected over All adverse events occurring between the start of treatment and end of the residual effect period, 7 days after the last dose of medication. Up to 95 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/36 (0%)7/36 (19.4%)3/36 (8.3%)
Empagliflozin 10mg0/35 (0%)1/35 (2.9%)8/35 (22.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboEmpagliflozin 10mg
Cardiac failure congestiveCardiac disorders2/360/35
Acute kidney injuryRenal and urinary disorders2/361/35
HypomagnesaemiaMetabolism and nutrition disorders0/361/35
Cardiac arrestCardiac disorders1/360/35
Cardiac failureCardiac disorders1/360/35
GlaucomaEye disorders1/360/35
Lower respiratory tract infectionInfections and infestations1/360/35
Euglycaemic diabetic ketoacidosisMetabolism and nutrition disorders1/360/35
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/360/35
SyncopeNervous system disorders1/360/35
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10mg
Urinary tract infectionInfections and infestations1/363/35
OsteoarthritisMusculoskeletal and connective tissue disorders0/362/35
PruritusSkin and subcutaneous tissue disorders0/362/35
Lower respiratory tract infectionInfections and infestations2/361/35

Baseline characteristics

Randomised set (RS): This set included all patients who were randomised to study treatment, in line with the intention-to-treat principle.

Age, Continuous
Age, Continuous(Years)Placebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort BTotal
Mean64.7 ± 12.772.1 ± 7.067.5 ± 14.169.1 ± 10.968.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort BTotal
Female697830
Male139101042
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort BTotal
Hispanic or Latino00000
Not Hispanic or Latino1918171872
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort BTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White1918171670
More than one race00000
Unknown or Not Reported00000
Ratio of phosphocreatine to adenosine triphosphate concentration
Ratio of phosphocreatine to adenosine triphosphate concentration(Ratio)Placebo Cohort APlacebo Cohort BEmpagliflozin 10mg Cohort AEmpagliflozin 10mg Cohort BTotal
Mean1.924 ± 0.3541.719 ± 0.4311.889 ± 0.4071.896 ± 0.4621.859 ± 0.413
08

Study locations

1 site
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Hundertmark MJ, Agbaje OF, Coleman R, George JT, Grempler R, Holman RR, Lamlum H, Lee J, Milton JE, Niessen HG, Rider O, Rodgers CT, Valkovic L, Wicks E, Mahmod M, Neubauer S. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Fail. 2021 Aug;8(4):2580-2590. doi: 10.1002/ehf2.13406. Epub 2021 May 6. PubMed 33960149 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in May 2020, 26 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 26 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 6, 2017
StartActual
Mar 1, 2018
Primary completionActual
May 21, 2020
CompletionActual
May 28, 2020
Results first posted
Jun 18, 2021
Last update
Jun 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03332212
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Mar 1, 2018
Primary completion
May 21, 2020
Completion
May 28, 2020
Results posted
Jun 18, 2021
Last update
Jun 18, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion